CASI CASI Pharmaceuticals Inc.

3.3
-0.04  -1%
Previous Close 3.34
Open 3.31
Price To Book 2.9
Market Cap 315866272
Shares 95,717,052
Volume 154,710
Short Ratio
Av. Daily Volume 202,038

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 completed. Will not further development.
ENMD-2076
Cancer - Advanced/Metastatic Soft Tissue Sarcoma
Phase 2 initiated July 2012. Noted April 14, 2017 that further patient enrollment has been stopped.
ENMD-2076
Cancer - triple-negative breast cancer
Phase 2 initiated October 2015.
ENMD-2076
Cancer - fibrolamellar carcinoma (FLC)

Latest News

  1. INVESTOR ALERT: Monteverde & Associates PC Launches an Investigation of the Board of Directors and Officers
  2. CASI Pharmaceuticals In-Licenses Exclusive Worldwide Rights to Novel Anti-CD38 Monoclonal Antibody Program From Black Belt Therapeutics
  3. CASI Pharmaceuticals Announces The Appointment Of Wei-Wu He, Ph.D., Executive Chairman, To The Role Of Chief Executive Officer
  4. CASI Pharmaceuticals Announces Fourth Quarter And Full Year 2018 Financial Results And Business Results
  5. CASI Pharmaceuticals Announces Exclusive Distribution Partner For Melphalan Hydrochloride For Injection (EVOMELA®) In China
  6. CASI Pharmaceuticals Announces China National Medical Products Administration (NMPA) Approval Of CTA To Conduct Registration Trial For MARQIBO®
  7. When Will CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Turn A Profit?
  8. Report: Developing Opportunities within Pure Storage, Flowers Foods, Cognex, CASI Pharmaceuticals, Ellie Mae, and Douglas Emmett — Future Expectations, Projections Moving into 2019
  9. CASI Pharmaceuticals Announces China National Medical Products Administration (NMPA) Approval Of CTA To Conduct Confirmatory Clinical Trial For ZEVALIN®
  10. CASI Pharmaceuticals to Present at the BIO CEO & Investor Conference
  11. These 4 Healthcare Stocks Are Heating Up
  12. Do Institutions Own Shares In CASI Pharmaceuticals, Inc. (NASDAQ:CASI)?
  13. The 4 Healthcare Stocks To Watch On Monday
  14. CASI Pharmaceuticals Announces China Market Approval Of Melphalan Hydrochloride For Injection (Trademark: EVOMELA®)
  15. Report: Exploring Fundamental Drivers Behind CASI Pharmaceuticals, Booking, Enstar Group, Madrigal Pharmaceuticals, Dermira, and Kaiser Aluminum — New Horizons, Emerging Trends, and Upcoming Developments
  16. CASI Pharmaceuticals To Build GMP Manufacturing Site In Wuxi, China
  17. CASI Pharmaceuticals Announces Third Quarter and First Nine Months 2018 Financial and Business Results
  18. Today’s Research Reports on Stocks to Watch: CASI Pharmaceuticals and Therapix Biosciences
  19. Why CASI Pharmaceuticals Inc. Is Rocketing Higher Today